400 Farmington Avenue
Farmington, CT 06032
Phone: 860 679-2826 or 860 338-1758
Bioarray is a biotech company developing gene profiling tests to personalize cancer treatments. Bioarray developed the world’s first stratification test for Triple Negative Breast Cancer Patients, BA100. BA100 keeps approximately 67% of Triple Negative Breast Cancer Patients from an ineffective 4-6 months of standard-of-care chemotherapy. Eliminating ineffective standard-of-care chemotherapy treatment saves toxicity, time and costs.
The company is building differentiated biomarker libraries and machine learning algorithms. Bioarray’s machine learning algorithm processes 10,000+ iterations to provide best predictors of treatment sensitivity. Bioarray’s differentiated technology applies to at least 8 types of cancers including breast, lung, colon, prostate, ovarian and pancreatic cancers. Biomarkers were identified for tissue and liquid biopsies.